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There! are! similarities! between! tissue! repair! and! cancer! development.! Epithelial!
tumours!promote!the!formation!of!the!stroma!by!activation!of!the!wound!healing!
process,! but! unlike! healing! wounds! the! process! is! not! selfOlimiting.! Pigment!
epithelium!derived!factor!(PEDF)!is!a!secreted!glycoprotein!that!has!been!shown!to!
exhibit!multiple!biological!properties!including!antiOangiogenesis,!antiOtumorigenesis!
and! immuneOmodulation.! Previous! studies! demonstrated! that! PEDF! expression! is!




study!were! to! elucidate!more! detailed! regulatory!mechanisms! of! PEDF! in!wound!




lines!and! tissue!and! that! treatment!with! recombinant!PEDF!resulted! in! significant!
decreases! in! the! rate! of! colorectal! cancer! cellular!migration! and! invasion! and! an!
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proteins! and! is! controlled! by! cytokines! and! growth! factors! (Harding! et! al.! 2002;!
Gurtner!et!al.!2008;!Haertel!et!al.!2014).!The!stages!of!the!wound!healing!process,!




reflex! mechanisms! cause! rapid! constriction! of! injured! vessels! by! contraction! of!
vascular!smooth!muscle!cells,!and!endothelial!cells,!platelets!and!coagulation!factors!
interact,!to!achieve!haemostasis.!!Platelets!trapped!within!the!fibrin!rich!wound!clot,!
composed! of! fibronectin,! vitronectin,! fibrin! and! thrombospondin,! trigger! an!
inflammatory!response!by!the!release!of!vasodilators,!(e.g.!serotonin),!cytokines,!(e.g.!
tumour! necrosis! factorO! α! (TNFO! α),! transforming! growth! factorO! β! (TGFO! β)),! and!
growth! factors,! (e.g.! vascular! endothelial! growth! factor! (VEGF),! plateletOderived!








Polymorphonuclear! neutrophils,! activated! by! proOinflammatory! cytokines! such! as!
TGFO!β,!remove!bacteria!and!debride!devitalised!tissue,!via!a!release!of!antimicrobial!
substances!and!proteases!(Weiss.!1989;!Su!&!Richmond.!2015).!Polymorphonuclear!
neutrophils! are! also! responsible! for! the! release!of! proOangiogenic! factors! such! as!
VEGFOA,!and!therefore!are!an!important!trigger!for!wound!angiogenesis!(Schruefer!
et! al.! 2006).! ! Following! this,! macrophages,! the! majority! recruited! from! blood,!
predominate!in!the!wound!regulated!by!!a!number!of!different!chemotactic!factors!
including!growth!factors,!chemokines!and!proOinflammatory!cytokines,!which!are!all!








Neovascularisation! begins! to! occur! in! the! fibrin! rich!wound! clot.! This! is! in! direct!
response! to! soluble! mediators! being! released! by! macrophages! during! the!
inflammation! stage! as! described! above.! Activated! endothelial! cells! respond! by!





















wound! bed! resulting! in! re*epithelialisation,! via! synthesis! of! proteases! and!
components!of!the!basal!lamina!(Gurtner!et!al.!2008).!!
4.!Remodelling!Stage.!












pre*existing! blood! vessels! (Figure! 1.2)! (Ribatti! &! Crivellato.! 2012).! The! activated!
endothelial!cells!release!proteases!that!degrade!the!basement!membrane!to!allow!
the!endothelial!cells!to!escape!vessel!walls.!Endothelial!cells!then!proliferate!into!the!
surrounding! matrix! and! form! solid! sprouts! connecting! neighbouring! vessels.! As!








In! normal! physiological! conditions,! angiogenesis! occurs! primarily! in! embryonic!
development,! in! response! to!ovulation! and! in! the!normal!wound!healing!process!
(Folkman! 1971).! However,! in! pathological! conditions! the! steady! state! of! the!
angiogenesis! system! is! disrupted! and! endothelial! cells! of! the! microvasculature!
proliferate,! migrate,! and! form! new! but! leaky! vessels! that! can! invade! the! tissue!
(Folkman! 1971;! Carmeliet! &! Jain! 2011).! Pathological! angiogenesis! has! been!
implicated! in! a! range! of! diseases! including! psoriasis,! age*related! macular!
degeneration,!diabetic!retinopathy!and!in!particular!cancer!(Heidenreich!et!al.!2009;!


























malignant! changes! can!occur! in! the!presence!of! chronic! inflammatory! conditions,!
such!as!Helicobacter+pylori+related!oesphagogastric!inflammation,!ulcerative!colitis!
and! chronic! hepatitis! (Dunham.! 1972).! These! clinical! observations! reinforced! the!
hypothesis!that!there!must!be!similar!cellular!mechanisms!in!both!tissue!repair!and!










as!macrophages,! produce! inflammatory! cytokines! during! both! wound! repair! and!
tumorigenesis.!In!established!tumours,!these!tumour!derived!cytokines!promote!the!







species! that! can! directly! damage! DNA! and! alter! proteins! that! regulate! cell! cycle!
control!and!apoptosis!(Allavena!et!al.!2008;!Hanahan!&!Weinburg.!2011).!However,!
the!main!contrast!between!tumours!and!wounds!is!related!to!the!invasive!growth!of!
the! transformed!keratinocytes! (Schäfer!et!al.!2008).!As!discussed! in!section!1.1.2,!
angiogenic!processes!are!also!similar!between!both!wound!repair!and!tumorigenesis,!
however! the! tight! control! regulating! the! balance! of! pro*! and! anti*angiogenic!










Pigment!epithelium*derived! factor! (PEDF),! also! known!as!early!population!double!
level! cDNA*1! (EPC1),! is! a! secreted! glycoprotein.! It! was! first! identified! when!
Tombrank*Tink’s!group!were!studying!human!retinal!cell!development.!They!found!a!









serine! protease! inhibitors! are! a! group! of! proteins! that! have! a! common! three*











1994),! which! is! the! most! frequent! target! gene! for! genetic! alterations! in! human!
cancers! (Hollstein!et!al.!1997).!To!date,! the!PEDF!gene!has!only!been!detected! in!







evidence! that! PEDF! is! pleotropic! with! multiple! biological! properties! including!
neuroprotective,! anti*angiogenic,! anti*tumorigenic! and! immune*modulating!
(Becerra!et!al.!2013;!Zhang!et!al.!2006b).!!
1.3'The'role'of'PEDF'in'angiogenesis''
PEDF! has! been! demonstrated! to! be! one! of! the!most! potent! natural! inhibitors! of!
angiogenesis,!more!so!than!angiostatin,!endostatin!and!thrombospondin*1!(Dawson!
et! al.! 1999;! Duh! et! al.! 2002).' PEDF! exerts! anti*angiogenic! activities! by! arresting!
endothelial!cell!proliferation!and!migration,!and!has!been!shown!to!occur!even!in!the!
presence! of! VEGF! (Dawson! et! al.! 1999;! Volpert! et! al.! 2002;! Bouck! 2002).! The!
mechanisms!of!action!appear!to!be!multifactorial!(Figure!1.5).!It!is!suggested!that!the!
underlying! mechanism! of! PEDF! biological! effects! on! endothelial! cells! involve! a!
complex!cross!talk!between!the!signal!events!triggered!by!both!pro*angiogenic!and!
anti*angiogenic! molecules.! It! has! been! proven! that! PEDF! upregulates! gamma!
secretase!effects,!which!in!turn!leads!to!cleavage!of!the!vascular!endothelial!growth!
factor! receptor! (VEGFR)! transmembrane! domain,! thereby! limiting!VEGF! signalling!
and!inhibiting!angiogenesis!(Cai!et!al.!2006).!Evidence!also!supports!the!concept!that!


























apoptosis! in! actively! remodelling! vessels! via! Fas/FasL! death! receptor! signalling!
(Zaichuk!et!al.!2004;!Elayappan!et!al.!2009).!!
It!has!been!demonstrated!that!the!34*mer!fragment!of!PEDF!(residues!24*57)!exhibits!
the! anti*angiogenic! effects! and! the! 44*mer! fragment! (residues! 58*101)! the!
neurotrophic! effects! (Filleur! et! al.! 2005),! highlighting! that! different! fragments! of!
PEDF!seem!to!be!responsible!for!different!activities.!!












Colorectal!cancer! is! the! fourth!commonest!cancer! in!the!UK,!with!an! incidence!of!
approximately!41,000!new!cases! in!2013!and!an!estimated!1.36!million!diagnosed!

















It! is! recognised! that!primary! colonic! tumours!with!metastasis! are!associated!with!
increased! expression! of! VEGF! and! increased! vascular! density! when! compared! to!
those!without!metastasis! or! benign! adenomas,! and! that! the! invasive! edge!of! the!
colonic!tumour!contains!!a!higher!vascular!density!than!other!areas!of!the!tumour!
indicating!the!role!of!VEGF!in!tumour!metastatic!spread!(Takahashi!et!al.!1995).! It!
was! initially! recognised! that! the! VEGF! ligand! VEGF*A! is! a! key! driver! of! sprouting!
angiogenesis! and! can! be! overexpressed! in! a! number! of! solid! tumours,! and! in!
particular,! colorectal! cancer! (Ellis! et! al.! 2008).! Early! work! involving! a! murine!




































the! anti*human!globulin! response.! Few!of! these!humanised!monoclonal! antibody!
anti*angiogenic! therapies! have! been! proven! to! have! clinical! benefit! in! colorectal!
cancer!patients.!One!of!the!first!reported!randomised!clinical!trial!of!the!use!of!the!
anti*VEGF*A! therapy! Bevacizumab! (Avastin®)! in! humans! was! published! in! 2003!
(Kabbinavar!et!al.!2003).!This!phase!II!trial!randomised!metastatic!colorectal!cancer!
patients! to! receive!either! treatment!with!Bevacizumab!10mg/kg!every! two!weeks!
plus! chemotherapy! (FU/LV),! Bevacizumab! 5mg/kg! every! two! weeks! plus!
chemotherapy! or! chemotherapy! alone.! Their! results! demonstrated! a! significantly!
higher! response! rate! with! the! 5mg/kg! treatment! dose! of! Bevacizumab! plus!
chemotherapy! when! compared! to! chemotherapy! alone,! and! an! increased!
progression*free!survival!in!both!of!the!Bevacizumab!treatment!groups.!The!authors!




to! chemotherapy! alone,! as!well! as! overall! survival,!were! confirmed! in! a! Phase! III!
randomised! control! trial! the! following! year! (Hurwitz! et! al.! 2004).! Following! these!






a! plethora! of! evidence! to! support! the! use! of! Bevacizumab! in! combination! with!
standard! chemotherapy,! in! selected! patients! for! the! treatment! of! metastatic!
colorectal!cancer!(Table!1.3!and!1.4),!as!well!as!metastatic!breast!cancer,!(Miller!et!
al.!2005),!renal!cancer!!(Yang!et!al.!2003)!and!non*small!cell!lung!cancer!(Sandler!et!
al.! 2006).! However,! there! is! currently! a! lack! of! evidence! to! support! the! use! of!
Bevacizumab!as!an!adjuvant! treatment! in!non*metastatic! colorectal! cancer! (Table!
1.2).!!
Despite! the! increasing! publication!of! evidence! for! the! use! of! Bevacizumab! in! the!
treatment!of!metastatic!colorectal!cancer,! in!2010!the!National!Institute!of!Health!
and! Care! Excellence! (NICE)! issued! guidance! that! did! not! support! the! use! of!
Bevacizumab!in!colorectal!cancer!within!the!UK!(NICE.!2010).!This!decision!was!based!
on!several!criteria.!Firstly,!the!use!of!FOLFIRI!as!first!line!chemotherapy!has!declined!
within! the!UK,! in! favour!of! chemotherapy!agents!with!better! clinical! efficacy! and!
lower!adverse!effects;!therefore,!studies!using!FOLFIRI!should!not!been!considered!
as!gold!standard!as!a!comparator!to!novel!therapies.!Secondly,!concerns!arose!over!




showed! only! a! statistical! significant! increase! in! progression*free! survival! but! not!
overall!survival!(Saltz!et!al.!2008).!NICE!concluded!that!whilst!the!first*line!treatment!





































































































































































































































































































































































































































































































































































































































































































































































of! Bevacizumab! for! second*line! treatment! of! metastatic! colorectal! cancer! (NICE.!
2012).!!
A! further! anti*VEGF! therapy! has! been! proposed! for! use! in! colorectal! cancer;!
Aflibercept! (Zaltrap®)! is! a! novel! fusion! protein! that! binds! to! three! VEGF! ligands!
(VEGF*A,! VEGF*B! and! placental! growth! factor! (PlGF)).! As! Aflibercept! also! targets!
VEGF*B!and!PlGF,!not!just!VEGF*A!like!Bevacizumab,!it!has!been!hypothesised!that!it!
may! confer! additional! anti*angiogenic! effects! (Fischer! et! al.! 2008).! A! Phase! III!
randomised!trial!in!2012!investigated!the!benefit!of!the!addition!of!Aflibercept!given!
with! chemotherapy! (FOLFIRI)! compared! to! chemotherapy! alone! in! patients! with!





Cetuximab! (Erbitux®)! is! an!epidermal! growth! factor! receptor! (EGFR)! inhibitor! and!
works!as!a!chimeric!monoclonal!antibody.!The!CRYSTAL!study,!a!Phase!III!randomised!
clinical! trial,! published! in! 2009,! compared! the! use! of! Cetuximab! plus! FOLFIRI! vs.!
FOLFIRI! alone! as! first*line! treatment! for! metastatic! carcinoma! of! the! colon! and!














2009).! ! Shortly! after! these! publications,! the! FDA! approved! Cetuximab! for! the!
treatment!of!colorectal!cancer!with!wild*type!KRAS!(USFDA.!2010).!In!the!UK,!NICE!
recommended! the! use! of! Cetuximab! in! combination! with! FOLFOX! (or! FOLFIRI! if!
intolerant!of!Oxaliplatin)!for!the!first*line!treatment!of!patients!with!EGFR*expressing!
KRAS! wild*type! metastatic! colorectal! cancer! with! the! following! criteria;! Primary!
(completely!resected!or!potentially!operable)!colorectal!tumour!with!unresectable!
metastasis!confined!to!the! liver!and!the!patient! is!deemed!fit!enough!for!primary!




fully! human! monoclonal! antibody.! One! Phase! III! randomised! control! trial! has!
demonstrated!an!increase!in!progression*free!survival!in!the!first*line!treatment!for!









gene! status! appears! to! be! a! predictive! marker! of! the! anti*EGFR! monoclonal!
antibodies,!with!evidence! supporting! that!mutant!KRAS!does!not! confer!a! clinical!
benefit!of!anti*EGFR!therapies!(Amado!et!al.!2008)!(Figure!1.6).!
Several! other! anti*angiogenic! agents! have! been! proposed! for! the! treatment! of!
metastatic!colorectal!cancer!by!mono*!or!poly*receptor!tyrosine!kinase!inhibition!(i.e.!
inhibit!downstream!receptor!signalling);!Cediranib!(AZD2171,!Recentin™),'Vatalanib!
(PTK! 787/ZK22584),! Regorafenib! (Stivarga),! Brivanib! and! Sunitinib! (Sutent®).!
However!apart!from!Regorafenib,!results!from!Phase!III!randomised!control!trials!do!
not! currently! support! their! use! in! the! treatment! of! metastatic! colorectal! cancer!
(Table!1.3!and!1.4).!!
Clearly! these! anti*angiogenic! therapies! show! promise! for! treatment! of! colorectal!
cancer,! nevertheless! the! outcomes! discussed! in! this! section! highlight! some!
disappointing! results! within! phase! III! clinical! trials,! with! only! one! anti*angiogenic!
therapy! (Cetuximab)! recommended! to! date! for! use! in!metastatic! colorectal! KRAS!
wild*type! tumours! in! the! UK.! Therefore,! there! is! a! desperate! need! to! seek! out!
























poorer!prognostic! clinical! features.!Comparing! cancer! tissue! specimens! to!normal!




A! significant! correlation!between! low!PEDF! expression! and! increased!microvessel!
density! (MVD)! was! found! in! breast! adenocarcinoma! (Zhou! et! al.! 2010),!








in! cases!of! lymph!node! involvement,! in! breast! cancer! (Cai! et! al.! 2006b)! and! lung!
cancer! (Fitzgerald! et! al.! 2012).! There! is! evidence! to! support! that! this! expression!
pattern!is!similar!in!the!presence!of!metastasis!within!breast!cancer!(Cai!et!al.!2006b;!







Low! levels! of! PEDF! expression! directly! correlate! with! overall! and! disease! *free!
survival,!in!breast!cancer!(Zhou!et!al.!2010),!pancreatic!cancer!(Seo!et!al.!2000)!and!
lung! cancer! (Chen! et! al.! 2009).! Zhou!et+ al! (2010)! demonstrated! that!multivariate!
analysis!of!overall!survival!using!Cox!regression!confirmed!PEDF!positivity!to!be!an!
independent! favourable! prognostic! factor! in! breast! cancer! (risk! ratio! 2.203,!
P=0.0062).!
PEDF! is! thought! to! inhibit! tumour! growth! and! metastasis! by! suppressing!
angiogenesis,!inhibiting!tumour!cell!proliferation,!increasing!tumour!cell!apoptosis,!
and/or! decreasing! tumour! cell! migration! and! invasion.! Several! studies! have!
investigated! the! effects! of! the! administration! of! recombinant! PEDF! (rhPEDF)! on!
tumour!cellular!function.!A!reduction!in!tumour!cellular!proliferation!was!found!in!a!
range!of!cancers!upon!administration!of! recombinant!PEDF,! including! lung!cancer!
(Chen!et!al.!2009),!breast!cancer!(Hong!et!al.!2014),!ovarian!cancer!(Cheung!et!al.!






















colorectal! cancer!patients! compared! to!healthy! controls! (median!1.6µg/ml! (range!
0.1*4.8µg/ml)!cf.!3.6µg/ml!(range!1.1*7.2µg/ml)!respectively,!p<0.001).!Interestingly,!
the!results!also!revealed!that!plasma!PEDF!levels!were!significantly!lower!in!healthy!
female! controls! compared! to!healthy!male! controls! (median!3.1µg/ml! (range!1.5*





colorectal! adenoma!and!healthy! controls! (Ji! et! al.! 2013).!All! serum! samples!were!
collected! pre*operatively! and! none! of! the! patients! had! received! neoadjuvant!





in! patients! with! colorectal! cancer! compared! to! normal! subjects! (p<0.0001).! No!
difference! was! found! between! patients! with! colorectal! adenoma! and! healthy!
subjects!or!between!preoperative!and!postoperative!serum!PEDF!levels!in!patients!
with! colorectal! cancer.! ! Serum!PEDF! levels! decreased! significantly!with! increased!
TNM!colorectal! tumour! staging! and! low! serum!PEDF! levels!were! observed! in! the!
presence! of! liver! metastases! (p<0.0001).! Of! interest,! cases! of! mucinous!








using! the!median! levels! of! protein! as! the! cut*off! for! the! definition! of! subgroups.!
Patients!with! lower! PEDF! levels!were! associated!with! significantly! shorter! overall!
survival!than!those!with!higher!PEDF!levels!(p=0.003),!but!no!significant!difference!
was!observed!in!disease*free!survival.!This!was!also!confirmed!on!a!further!training!









level! findings! (Ji! et! al.! 2013).! The! results! showed! that! downregulation! of! PEDF!
significantly!correlated!with!advanced!clinical!stage,!lymph!node!metastasis,!distant!































properties! (ΔTAp73);! its! interaction!with!VEGF!remains!unclear.!The!results!of! the!
study! found! that! median! mRNA! geometric! average! for! the! colorectal! cancer!





area! may! have! led! to! confusing! results! dependent! on! the! primers! used.! The!








had! high! levels! of! ΔEx2p73! (defined! as! transcript! copy! number! higher! than! 0.66,!
based!on!the!median!value)!(p=0.005,!r=0.463),!and!an!inverse!correlation!between!













in! thrombospondin*1! expression,! supporting! theories! that! PEDF! can! upregulate!
thrombospondin*1! (Guan! et! al.! 2004).! Furthermore,! treatment! with!
cyclophosphamide! resulted! in! fewer! lung!metastases! in!mice!bearing!KM12/PEDF!
tumours!compared!with!KM12/WT,!with!confirmation!achieved!by!immunostaining.!
Similar!findings!were!confirmed!by!Li!et+al!(2012);!the!PEDF!gene!was!delivered!by!










p63!and!p73,!but!not!p53,!downregulating!PEDF!expression.! In! colorectal! tumour!
xenografts,! vector!delivered!PEDF!was! found! to!decrease!microvessel!density!but!
with! conflicting! results! on! its! effect! on! tumour! growth! rate.! There! is! evidence! to!
support!that!administration!of!exogenous!PEDF!in!other!solid!tumours!can!result!in!
a!decline!in!cellular!proliferation,!inhibit!cellular!migration!and!invasion!and!induce!





As! discussed! in! section! 1.2,! not! only! does! PEDF! have! anti*angiogenic! and! anti*









blocked! by! PEDF,! suggesting! that! PEDF! inhibited! VEGF*induced! endothelial!
permeability!by!blocking!dysregulation!of!tight!junction!protein.!




al! (2011)! found! the! levels! of! pro*inflammatory! factors!were! significantly! lower! in!
PEDF!transgenic!mice!(express!human!PEDF!driven!by!β*actin!promoter)!compared!






The! link! between! PEDF! treatment! and! its! effect! on! inflammation! has! also! been!
investigated.!Zha!et+al!(2016)!conducted!an!in+vivo!experiment!on!mice!with!chronic!
ovalbumin*induced! asthma! treated!with! recombinant! PEDF! and! found! that! PEDF!























for! use! in! treatment! of!wounds! (Barrientos! et! al.! 2008;! Buchberger! et! al.! 2010).!











Another!novel!area!of! targeted! therapy! is!aimed!at! the!excessive!protease! levels,!
which!can!often!be!found!in!chronic!wounds!(Cullen!et!al.!2002;!Gibson!et!al.!2010).!
Excessive!protease!levels!can!result!in!degradation!of!growth!factors,!and!addressing!
this! may! prevent! this! degradation.! Conversely! treatment! to! address! excessive!
protease!levels!on!wounds!that!do!not!have!excessive!protease!levels!can!result!in!





2007).! A! randomised! control! trial! investigated! the! use! of! a! collagen/oxidised!
regenerated!cellulose!dressing!compared!to!standard!treatment!in!the!management!
of!diabetic!foot!ulcers!and!found!no!difference!in!terms!of!wound!closure!rates!at!12!
weeks! follow*up! between! both! treatment! arms! (Veves! et! al.! 2002).!
Collagen/oxidised!regenerated!cellulose!dressings!have!been!combined!with!silver!
therapy!(anti*microbial!properties)!and! its!use!has!been!assessed! in!a!randomised!
control! trial! in! patients!with! diabetic! foot! ulcers,! comparing! to! standard! therapy!









There! is! some! limited! evidence! from! a! randomised! control! trial! to! support! the!
combined! treatment! with! protease*modulating! matrix! and! autologous! growth!




are! thought! to! migrate! to! wounded! tissue! and! secrete! chemokines! and! growth!
factors! in! order! to! promote! angiogenesis! and! ECM! remodelling! (Blumberg! et! al.!
2012).!They!can!be!categorised!into!allogenic!and!autologous!stem!cells,!based!on!
their!source.!Allogenic!stem!cells!include!placental!or!amnion*derived!mesenchymal!
and! embryonic! stem! cells.! Autologous! stem! cells! include! bone! marrow! derived!
endothelial! progenitor! cells,! bone!marrow!derived!mesenchymal,! haematopoietic!
and! adipose*derived! stem! cells.! Although! the!use!of! stem! cells! is! promising! from!
animal!studies,!only!one!randomised!control!trial!has!investigated!the!use!of!stem!
cells!in!diabetic!foot!ulcers.!Lu!et+al!compared!bone!marrow!mesenchymal!stem!cells!
with! bone! marrow*derived! mononuclear! cells! and! found! the! healing! rate! was!












by! the! clinician,! can! be! the! identification! of! the! wounds! that! will! respond! to! a!
particular!treatment,!and!the!development!of!clinical!biomarkers!may!be!beneficial.!







in!HECV!cell! lines!(endothelial!cell! line!originating!from!human!umbilical!vein)! in!a!
study! by! Cai! et+ al! (2006b).! Expression! has! also! been! detected! in! HaCaT! (human!
keratinocyte)!cell!line!(Li!et!al.!2011).!!
mRNA!detection!of!PEDF!was! found! in! the!dermal! layer!of! the!skin! (Francis!et!al.!










but!was!stronger! in! the!epidermis! than!dermis.!However! in!contrast,!Francis!et+al!
(2004)! found! PEDF! protein! localised! to! the! sub*epidermal! region! determined! by!
immunofluorescence!on!normal!skin!tissue!specimen.!On!a!cellular!level,!expression!
of! PEDF! protein! was! found! to! be! localised! to! the! cytoplasm! of! keratinocytes! on!







decline! was! witnessed! between! young! and! middle! aged! donors,! suggesting! that!
reduction!of!PEDF!expression!may!be!an!early!aging!event!that!alters!the!complex!
homeostatic!balance!of!angiogenic!modulators!in!the!skin!tissue!microenvironment.!!
Abe! et+ al,! (2010)! found! that! cultured! keratinocytes! stimulated! with!
lipopolysaccharide!constitutively!secrete!PEDF!(as!determined!by!ELISA!analysis!of!
PEDF!concentration!in!the!collected!media!1!day!after!stimulation),!and!the!secretion!
was! significantly! upregulated! in! a! dose! dependent! manner,! whereas! cultured!




fibroblasts! secrete! PEDF! in! a! regulated! manner! in! response! to! inflammation.!
Furthermore,! Sarojini! et+ al! suggested! that! conditioned! medium! (secretome)! for!
mouse!mesenchymal!stem!cells!is!chemotactic!for!human!fibroblasts,!and!that!PEDF!
is! the! predominant! fibroblast! chemoattractant,!with! immunofluorescence! studies!








4.62%! and! 23.91%! at! doses! of! 5ng/ml! and! 50ng/ml! respectively.! Flow! cytometry!





the! lower! dose! of! rhPEDF! 5ng/ml.! Scratch! migration! assays! showed! that! PEDF!
50ng/ml!decreased!wound!closure!rate!by!33%!and!29%!after!24!and!48!hours!of!
incubation,!when!compared!to!the!control!group!(p<0.001)!(no!treatment)!(Li!et!al.!
2011).! Work! by! Chen! &! Dipietro! (2014)! supported! these! findings! of! increased!




migration! rate! but!with! no! effect! noted!on! cellular! growth.! They! also! found! that!
treatment! with! inflammatory! cytokines! (IL*1β,! IL*6! and! TNF*α)! inhibited! PEDF!
expression!in!isolated!skin!keratinocytes.!In!mouse!dermal!burn!wound!models,!PEDF!
was! discovered! to! be! downregulated! at! 0! and! 2! hours! post*wounding! but!
upregulated!at! 3! and!14!days!post*wounding.! The! authors!hypothesised! that! this!
early! downregulation! of! PEDF! expression! may! be! because! of! the! high! rate! of!
inflammatory!cytokines,!such!as!IL*1β,!IL*6!and!TNF*α,!in!early!wound!environments!
(Chen!et!al.!2010)!or!due!to!disruption!of!the!keratinocyte!layer.!!
There! is! evidence! to! suggest! that! PEDF! expression! is! downregulated! in! chronic!
inflammatory! skin! conditions,! in! keeping! with! other! inflammatory! conditions! (as!
discussed! in! section! 1.5.1),! with! studies! evaluating! psoriasis! and! condyloma!
acuminatum!(Abe!et!al.!2010;!Dong!et!al.!2013).!The!low!levels!of!PEDF!expression!in!








been! shown! to! exhibit! anti*inflammatory! effects! in! other!pathological! conditions,!
which!may!be!beneficial!for!such!patients!with!chronic!wounds.!There!may!also!be!a!





to! chronic! wounds.! PEDF! is! selective! in! its! action! by! discriminating! between!
endothelial! cells! forming! new! vessels! and! those! from! pre*existing! vessels! and!
therefore!targeting!mainly!abnormal!angiogenesis!with!newly!forming!vessels!and!
avoiding! existing! vessels! (Bouck! 2002).! It! is! therefore! logical! that! PEDF! inhibits!








more! detailed! regulatory! mechanisms! of! PEDF! in! wound! healing,! and! tumour!




































that!were!present! for!at! least! six!months!and!deemed!non*infected!by!a!clinician!
within!the!Wound!Healing!Research!Team,!Cardiff!and!Vale!University!Health!Board.!
Ethical! approval!was!obtained! from!Cardiff! and!Vale! ethics! committee! (reference!
number!SJT/C617/08)!and!written!informed!consent!was!gained!from!the!patients,!
and!has!been!described!previously!(Bosanquet!et!al.!2012). A!6mm!punch!biopsy!was!














































line,! derived! from! ascites.! It! is!




















Fibroblast! Colorectal! fibroblast! cell! line!
























































histology! reports! were! used! for! the! collation! of! clinical! and! pathological! data!
preoperatively!and!during!the!immediate!postoperative!follow*up!period.!Details!of!








as! control.! Specimens!were! registered!and! stored!according! to!Human!Tissue!Act!
regulations.!All!specimens!were!analysed!anonymously.!Details!of!patient!age!and!
gender,! TNM! staging,! Dukes! stage! and! pathological! grade! were! provided! during!








synthesised! by! Sigma! Aldrich! (Poole,! Dorset,! UK).! The! software! described! above!
features! an! automated! search! for! reaction! conditions! and! possible! homology!
amplification! of! other! genes.! The! conventional! reverse! transcription! polymerase!
chain! reaction! (RT*PCR)! and! quantitative! PCR! (qPCR)! paired! forward! and! reverse!
primers!for!each!gene!reside!in!one!of!two!adjacent!exons.!Additionally,!the!amplified!


















GAPDH! GAPDHF8! GGCTGCTTTTAACTCTGGTA! 475!
! GAPDHR8! GACTGTGGTCATGAGTCCTT! 475!

























































Two! grams! of! Potassium! Chloride! (KCl),! 79.5g! Sodium! Chloride! (NaCl),! 2.1g! of!





One! gram! of! KCl! (Fisons! Scientific! equipment,! Loughborough,! UK)! 1g,! 5.72g! of!



























The! cell! lysis! buffer! was! prepared! by! dissolving! 50mM! Tris! (0.61g),! 5mM! EGTA!
(0.19G),! 150mM! NaCl! (0.87g)! and! 1ml! Triton! x100! in! 100ml! of! distilled! water.!
Protease!inhibitors!(phenylmethylsulfonyl!fluoride!(PMSF)!(100µg/ml!in!isopropanol),!



























































































and! sterile! equipment.! Cells! were! maintained! in! the! appropriate! supplemented!
media! (as! described! in! Table! 2.5)! and! routinely! sub*cultured! upon! reaching! 90%!
confluence.!Confluence!was!determined!by!assessing!the!coverage!of!cells!over!the!


















cellular! functional! assays,! was! performed! using! a! Neubauer! haemocytometer!
counting!chamber!(Mod*Fuchs,!Rosenthal,!Hawksley,!UK).!This!haemocytometer!was!













RKO! DMEM/Ham’s! F12! with! L*glutamine! medium! (Sigma*Aldrich,!
Dorset,! UK)! with! 5ml! antibiotics! (streptomycin! 0.1mg/ml,!
penicillin!100U/ml,!amphotericin!0.25!µg/ml)!and!50ml!Foetal!
Calf!serum!(10%)!
HT115! DMEM/Ham’s! F12! with! L*glutamine! medium! (Sigma*Aldrich,!
Dorset,! UK)! with! 5ml! antibiotics! (streptomycin! 0.1mg/ml,!
penicillin!100U/ml,!amphotericin!0.25!µg/ml)!and!50ml!Foetal!
Calf!serum!(10%)!
HRT*18! DMEM/Ham’s! F12! with! L*glutamine! medium! (Sigma*Aldrich,!
Dorset,! UK)! with! 5ml! antibiotics! (streptomycin! 0.1mg/ml,!
penicillin!100U/ml,!amphotericin!0.25!µg/ml)!and!50ml!Foetal!
Calf!serum!(10%)!
COLO*201! DMEM/Ham’s! F12! with! L*glutamine! medium! (Sigma*Aldrich,!
Dorset,! UK)! with! 5ml! antibiotics! (streptomycin! 0.1mg/ml,!
penicillin!100U/ml,!amphotericin!0.25!µg/ml)!and!50ml!Foetal!
Calf!serum!(10%)!
LS174T! DMEM/Ham’s! F12! with! L*glutamine! medium! (Sigma*Aldrich,!




5ml! antibiotics! (streptomycin! 0.1mg/ml,! penicillin! 100U/ml,!
amphotericin! 0.25! µg/ml),! hydrocortisone! (1µg/ml),! Basic!
Fibroblast! Growth! Factor! (FGFb)! (5ng/ml),! ascorbic! acid!
50µg/ml),!insulin!(5µg/ml),!glutamine!!(7.5mM)!and!20ml!Foetal!
Calf!Serum!(2%)!
HaCaT! DMEM/Ham’s! F12! with! L*glutamine! medium! (Sigma*Aldrich,!
Dorset,! UK)! with! 5ml! antibiotics! (streptomycin! 0.1mg/ml,!
penicillin!100U/ml,!amphotericin!0.25!µg/ml)!and!50ml!Foetal!
Calf!serum!(10%)!
HECV! DMEM/Ham’s! F12! with! L*glutamine! medium! (Sigma*Aldrich,!






5ml! antibiotics! (streptomycin! 0.1mg/ml,! penicillin! 100U/ml,!
amphotericin! 0.25! µg/ml),! hydrocortisone! (1µg/ml),! Basic!







MesenProRS! medium! (Life! Technologies,! Paisley,! UK)! with!
glutamine! (2mM),! 20ml! Foetal! Calf! Serum! (2%)! and!with! 5ml!







from! a! tissue! culture! flask! using! trypsin:EDTA! (as! described! in! section! 2.7.3).!
Following! detachment,! the! cells! were! resuspended! in! the! required! volume!


























The! resultant! cell! lysate! was! transferred! into! a! 1.8ml! microfuge! tube.! 0.2ml!








ethanol! (Fisher! Scientific,! Leicestershire,! UK)! prepared! in! DEPC! water,! and! then!
centrifuged!at!7,500rpm!for!5!minutes!at!4OC.!The!ethanol!was!then!removed!and!




Concentration! of! RNA! was! measured! using! an! Implen! Nanophotometer! (Implen,!












RNA!was! converted! into! complementary!DNA! (cDNA)! using! a! high! capacity! cDNA!
reverse! transcription! kit! (Applied! Biosystems,! Manchester,! UK).! Based! on! the!
Nanophotometer!reading,!PCR!water!was!added!to!the!RNA!solution!to!make!up!to!
a!total!volume!of!10µl!(standardised!values!of!250*500ng!of!RNA!and!PCR!water)!with!
10µl! of! RT!Mastermix! (10x! RT! buffer! (2µl),! 25x! dNTP!mix! 100mM! (0.8µl),! 10x! RT!
random!primers!(2µl),!MultiScibe!Reverse!transcriptase!(1µl),!RNase!inhibitor!(1µl)!












































































to! the! amount! of! DNA! that! has! been! amplified.! The! degree! of! fluorescence! in! a!
sample!was!compared!to!a! range!of!standards!of!known!transcript!copy!numbers!
(Figure!2.3).!This!permits!accurate!calculation!of!the!transcript!copy!number!in!each!






Microseal! (Bio*Rad! Laboratories,! Hemel! Hampstead,! UK).! This! was! placed! in! an!
iCyclerIQ!thermocycler!(Bio*Rad!Laboratories,!Hemel!Hampstead,!UK)!to!amplify!and!
quantify!the!cDNA!over!the!cycles!detailed!in!Table!2.10.!Specific!qPCR!primers!were!
verified! using! a! positive! control! know! to! express! the!molecule! of! interest! and! a!
negative! control,! where! PCR! water! replaced! cDNA! in! a! reaction,! to! rule! out!





























































Protein! quantification!was! undertaken! according! to! Bio*Rad! DC! Protein! Assay! Kit!
protocol!(Hemel!Hempstead,!UK)!in!order!to!standardise!the!concentration!of!protein!






read! at! 620nm! using! an! ELX800! plate! reading! spectrophotometer! (Bio*Tek,!Wolf!
Laboratories,!York,!UK).!A!standard!curve!was!created!using!an!equation!to!calculate!
protein!quantification!from!the!scatter! line!graph!of!spectrophotometer!results! in!
Microsoft! Excel! software! (Microsoft,! Washington,! USA),! therefore! allowing! the!
sample! concentrations! to! be! calculated.! Samples!were! normalised! to! the! desired!









described! in! Table! 2.11.! The! resolving! gel! was! poured! between! two! glass! plates!
within! the! loading! cassette,! to! 1.5cm! below! the! top! of! the! plate.! Once! set,! the!
stacking!gel!was!poured!on!top!and!a!comb!placed!until!set.!The!loading!cassette!was!
placed!into!an!electrophoresis!tank!and!filled!with!1x!running!buffer.!8µl!of!broad!













































Following!suction!of!all! visible!blocking!solution! the!primary!antibody!solution! (as!
described! in!section!2.5)!was!added!to!each!well!and! incubated!for!10!minutes!at!
room! temperature.! The! concentration! used! for! primary! antibodies!was! 1:150! for!
Anti*PEDF!polyclonal!antibody!and!1:400!for!Anti*GAPDH!polyclonal!antibody.!The!
vacuum! was! activated! and! washed! 3! times! using! TBST.! The! secondary! antibody!
solution!(as!described!in!section!2.5)!was!added!to!each!well!and!incubated!for!10!
minutes!at!room!temperature.!The!concentration!used!for!the!secondary!anti*!rabbit!
IgG! peroxidase! conjugate! concentration!was! 1:500.! ! The! vacuum!was! once! again!
reactivated! and!washed! 3! times! using! TBST.! Following! suction! of! all! visible!wash!
buffer! solution! the!membrane!was! removed! ready! for! chemiluminescent! protein!
detection.!!
All!volumes!used!for!solutions!outlined!above!were!titrated!to!well!size!as!per!the!















Immunohistochemistry!was! performed!using!Vector!ABC! kit! (Vector! Laboratories,!
Burlingame,! California,! USA)! as! described! previously! (Wang! et! al.! 2016).! The!























minutes.! The! slides!were! then! dehydrated! for! 5!minutes! in! each! of! 50%! ethanol!
(Fisher!Scientific,!Leicestershire,!UK),!70%!ethanol!(Fisher!Scientific,!Leicestershire,!
UK),! 90%! ethanol! (Fisher! Scientific,! Leicestershire,! UK),! 100%! ethanol! (Fisher!
Scientific,! Leicestershire,! UK),! 100%! ethanol! (Fisher! Scientific,! Leicestershire,! UK),!
50%! ethanol/50%! xylene! (Fisher! Scientific,! Leicestershire,! UK),! and! finally! 100%!
xylene!(Fisher!Scientific,!Leicestershire,!UK).!The!samples!were!mounted!with!DPX!
Mountant!and!a!coverslip!(Fisher!Scientific,!Leicestershire,!UK).!!
All! samples! were! run! against! a! negative! control! for! comparison! purposes.! The!
samples!were!visualised!using!a!Leica!DM!1000!LED!microscope!(Leica!Microsystems!
Ltd,!Milton!Keynes,!UK)!at!x100!magnification.!Software!used!capture! images!was!
















in! 2.6.4,! for! 1!hour! in! a! humidified!box,! followed!by! incubation!with! the!primary!



















UK),! 100%!ethanol! (Fisher! Scientific,! Leicestershire,!UK),! 50%!ethanol/50%! xylene!
(Fisher! Scientific,! Leicestershire,! UK),! and! finally! 100%! xylene! (Fisher! Scientific,!
Leicestershire,!UK).!The!samples!were!mounted!with!DPX!Mountant!and!a!coverslip!
(Fisher!Scientific,!Leicestershire,!UK).!!
All! samples! were! run! against! a! negative! control! for! comparison! purposes.! The!
samples!were!visualised!using!a!Leica!DM!1000!LED!microscope!(Leica!Microsystems!
Ltd,!Milton!Keynes,!UK)!at!x100!magnification.!Software!used!capture! images!was!




chamber! slides! (Millipore,! Watford,! UK)! and! incubated! in! appropriate! growth!











three! times!with! TBS! followed! by! incubation!with! the! secondary! antibody! for! 30!
minutes.! Secondary! antibody!used!was! anti*! rabbit! IgG! FITC! conjugate! at! a! 1:250!
concentration!(as!described!in!section!2.5).!The!slides!were!one!again!washed!three!
times! in! TBS.! The! samples! were! mounted! with! Floursave! Reagent! (Millipore,!
Watford,!UK)!and!a!coverslip!(Fisher!Scientific,!Leicestershire,!UK).!!
All! samples! were! run! against! a! negative! control! for! comparison! purposes.! The!
samples! were! visualised! using! an! Olympus! BX51! polarising! microscope! at! x40!
magnification!(Olympus!KeyMed!Group!of!Companies,!Essex,!UK).!Software!used!to!
capture! images! was! cellSens! dimension! (OIympus! KeyMed! Group! of! Companies,!















cells/100µl,! and! then! the! cell! solution! was! supplemented! with! 100µl! of! either!
treatment!or!control.!The!plates!were!incubated!for!1,3!and!5!days!respectively!at!
37oC,!5%!CO2!and!95%!humidity.!After!incubation,!the!medium!was!removed!from!







Cell! growth! rates!were! presented! as! a! percentage! increase! for! both! 3! and! 5*day!
incubation!periods!compared!against!the!baseline,!absorbance!measured!at!day!1!
incubation.!At!least!three!wells!were!prepared!for!each!treatment!concentration!and!












ECIS! is! a! technique! that! measures! the! rate! of! cells! initial! attachment! and! then!
repopulation! of! an! area! following! electrical! wounding,! by! using! gold! electrodes!
within!a!well!plate!to!measure!changes!in!resistance!and!impedance!over!time!(Figure!
2.5!and!2.6)!(Keese!et!al.!2004).!Stabilisation!of!the!96!well!ECIS!electrode!array!plate!
(Applied! Biophysics! Inc.,! New! York,! USA)! in! contact! with! the! ECIS! Zθ! 96W! Array!
Station! (Applied! Biophysics! Inc.,! New! York,! USA)! in! an! incubator! at! 37°C! was!
performed! using! 200µl! of! normal! medium! in! each! well.! Once! stabilisation! was!
complete,!the!normal!medium!was!aspirated!and!a!solution!containing!10x104!cells!
per!150µl!was!prepared.!150µl!of!cell!solution!was!placed!in!each!well!of!the!96!well!
ECIS! electrode! array! plate! with! a! further! 150µl! of! either! treatment! with! varying!
concentrations!of!rhPEDF!or!normal!medium!added.!The!plate!was!then!reconnected!
to!the!ECIS!Zθ!96W!Array!Station.!Once!all!wells!had!reached!confluence!(determined!









































A! technique!using!an! in+ vitro!Matrigel! adhesion!assay! that!assessed! the!ability!of!

























entire! experimental! procedure! was! repeated! independently! a!minimum! of! three!
times.! Data! from! all! repeated! experimental! procedures! were! combined! and!
absorbance!levels!were!presented!as!a!marker!of!cell!density.!!
2.12.3'In'vitro'cellular'motility'assay''
Cellular! motility! was! assessed! using! one! of! the! two! methods! described! below,!






procedure! was! repeated! a! minimum! of! three! independent! times.! Data! from! all!






















The!methods!used!to!determine!the! invasive!ability!of! the!cells! in!this!study!have!
been!previously!described!(Fernando!et!al.!2010).!This!technique!has!been!modified!
from! the! originally! described! method! (Albini! et! al.! 1987;! Parish! et! al.! 1992)! to!
measure! cells! capacity! to! invade! through! an! artificial! basement! membrane! and!
migrate!through!8µm!pores.!!
Transwell!inserts!with!8µm!pores!(Falcon,!pore!size!8µm,!24!well!format,!Greiner!Bio*









through! the! insert! 1ml! of! normal! medium! was! placed! in! the! base! of! the! well!
containing! the! Transwell! insert.! Then! 3! x! 104! cells/100µl! solution! plus! 100µl! of!
treatment!or!normal!medium!were!added!to!each!insert.!These!were!incubated!for!
72!hours!at!370C,!5%!CO2!and!95%!humidity.!!
Following! incubation,! the! inserts!were! removed! from! the!well! plate,! the! solution!








be! performed! using! an! ELX*800! plate! reading! spectrophotometer! (Bio*Tek,! Wolf!
Laboratories,!York,!UK).!Cell!density!was!determined!measuring!absorbance!set!at!






















Two! 75cm2! flasks! of! confluent! cells! were! incubated! with! 2%! serum! medium!
overnight.!Each!75cm2!flask!of!cells!was!treated!with!either!treatment!of!50ng/ml!
rhPEDF!or!with!normal!medium!for!2!hours!prior!to!the!preparation!of!cell!lysates.!
Cells!washed! in!PBS!were! scraped! into!a!1.8ml!eppendorf! and! centrifuged! for!10!
minutes!at!2,000!rpm!until!a!cell!pellet!formed.!500µl!lysis!buffer!(100mM!Tris!Buffer,!
10%! 2*ME,! 1%! NP*40,! 50mM! NaFI! and! protease! inhibitor! cocktail! tablet! (Roche,!
Basel,!Switzerland))!was!added!and!rotated!on!blood!wheel!for!60!minutes!at!40C.!
Protein!quantification!was!then!performed!as!described!in!Section!2.9.2.!!









































































controls! (Wågsäter! et! al.! 2010;! Ji! et! al.! 2013)! with! lower! levels! correlating! with!
advanced!TNM!stage,!distance!metastasis!and!significantly!shorter!overall!survival,!
and!was!an!independent!risk!factor!for!colorectal!cancer!prognosis!(Ji!et!al.!2013).!
Interestingly! patients! with! mucinous! adenocarcinoma! patients! displayed! higher!
PEDF!serum!levels!than!adenocarcinoma!patients!(Ji!et!al.!2013).!!
Studies!examining!protein!levels!for!PEDF!expression!within!colorectal!cancer!tissue!

















The!aims!of! this! section!of! the!study!were! to!determine! the!expression!profile!of!












lines! are! described! in! Table! 2.1.! Cells! were! maintained! in! medium! as! described!
previously!in!section!2.7.1.!!
3.2.2'Colorectal'tissue'
Colorectal! cancer! tissue! collection! for! qPCR! was! performed! at! Beijing! Friendship!
Hospital,!China!as!described!in!section!2.3.!Colonic!cancer!tissue!microarray!(T054b)!




RNA! isolation!was! performed! using! TRI! reagent! kit! as! described! in! section! 2.8.1.!
Following!this,!reverse!transcription!was!carried!out!using!a!high!capacity!RT!kit.!RT*
PCR! products! were! separated! electrophorectically! on! an! agarose! gel.! RT*PCR!
representative! images! are! presented,! normalised! against! GAPDH.! qPCR! was!
performed! as! described! in! section! 2.8.8.! All! results! presented! were! normalised!
against!GAPDH!and!represent!combined!results!from!at!least!3!independent!repeats.!!
3.2.4'Immunohistochemical'staining'of'tissues'
Tissue! arrays! used! are! described! in! section! 3.2.2.! Immunohistochemistry! was!
performed!using!Vector!ABC!Kit!as! is!described!in!full!detail! in!Section!2.10.1.!The!







RKO,! HT115! and! HRT*18! cell! lines! were! used! for! immunocytochemistry,! as!
representative!cell!lines!for!colorectal!cancer.!Immunocytochemistry!was!performed!
as!described! in!Section!2.10.2.!The!primary!antibody!used!was! rabbit!monoclonal!





Immunofluorescence! staining! was! performed! as! described! in! section! 2.11.! The!
primary! antibody! used! was! rabbit! monoclonal! antibody! against! PEDF! at! a! 1:50!
concentration!and!the!secondary!antibody!used!was!anti*!rabbit!IgG!FITC!conjugate!











expression!was! seen! in! the!COLO*201!metastatic! cell! line.!However,! these! results!
were!not!found!to!be!statistically!significant!(p=0.58).!
Immunofluorescence! and! Immunocytochemistry! showed! a! tendency! towards!















































Figure' 3.3.! Representative! immunofluorescence! images! for! RKO! cell! line.! X40!magnification! used.!









































3.3.2'Expression'of'PEDF' in'human'colorectal' cancer' tissues'and' the'association'
with'clinicopathological'characteristics'
The!cohort!used!for!qPCR!consisted!of!221!male!patients!and!185!female!patients,!












On! immunohistochemical! staining! highest! expression! of! PEDF! was! seen! within!
smooth!muscle,!endothelial!cells!and!fibroblasts!(Figure!3.8).!Tumour!expression!of!
PEDF!was!more!pronounced!in!well*differentiated!mucinous!adenocarcinomas!when!
compared! to! poorly! differentiated! mucinous! adenocarcinomas! and! all! grades! of!
adenocarcinoma!(Figure!3.9!and!3.10).!There!was!a!significant!decrease!in!expression!





















































































































































































































































and( B)( poorly( differentiated( adenocarcinoma( tissue( samples.( X200( magnification( used.( Scale( bar(










Figure' 3.10.( Representative( immunohistochemistry( images( for( A)( well( differentiated( mucinous(
adenocarcinoma( and( B)( poorly( differentiated( mucinous( adenocarcinoma( tissue( samples.( X200(
magnification(used.(Scale(bar(represents(100µm.(Red(arrow(shows(positive(tumour(cell(staining(in(the(
well(differentiated(mucinous(adenocarcinoma(sample.(Yellow(arrow(shows(no(staining(of(mucus.(Blue(




























worsening( grade( of( tumour,( as( demonstrated( by( a( statistical( significance( on(
immunohistochemistry( staining( and(with( a( trend(witnessed( in(mRNA( expression,(
confirming( the( association( between( loss( of( PEDF( expression( and( worsening(
oncological(prognostic(factors;(this(echoed(the(findings(of(Guan(et#al((2003)(where(
decreased(expression(of(PEDF(was(apparent(with(worsening(tumour(grade(in(glioma(
tissue.( However,( there(was( little( evidence( from( the( results( presented( to( support(
associations(between(other(negative(prognostic( factors,( such( as( advanced(Duke’s(
Stage,(T(stage(or(lymph(node(involvement,(and(PEDF(expression(levels;(whilst(there(
was(a(trend(towards(lower(expression(in(metastatic(colorectal(cell(line,(compared(to(
other( colorectal( cancer( cell( lines,( this(did(not( reach( significance,(and( results( from(
qPCR(and(immunohistochemistry(studies(did(not(support(this(either.((
Interestingly,( mRNA( expression( of( PEDF( was( observed( to( be( higher( in( female(
colorectal(cancer(patients(when(compared(to(male(colorectal(cancer(patients.(This(is(
contrary(to(both(Yamagishi(et#al((2006)(and(Wågsäter(et#al((2010)'who(established(







A( recent(population*based(analysis( study(of(164,996( colorectal( cancer(patients( in(
Germany( demonstrated( a( higher( age*adjusted( 5*year( survival( rate( in( females(




0.98*1.04).( When( analysing( patients( with( advanced( stage( disease,( older( women(
aged(>75(years(had(a(worse(survival(than(men.(Location(of(tumour(did(not(seem(to(
affect( survival.(These( findings(were(comparable( to( two(earlier( studies,( in(patients(
based(in(USA(and(Japan((Hendifar(et(al.(2009;(Koo(et(al.(2008),(with(younger(women(
have(a(survival(advantage(compared(to(younger(men,(but(with(the(opposite(pattern(
noted( in( older( patients.(One( of( the(main( reasons( suggested( for( this( effect( is( the(
favourable(effect(of(endogenous(female(sex(hormones((Franceschi(et(al.(2000).(Other(
reasons( include( increased( bowel( cancer( screening( uptake( amongst( females( and(
therefore(higher(proportion(of(early(stages(at(diagnosis(and(better(prognosis((Stock(
et( al.( 2011),( however(Majek(et# al( (2013)( found( a( survival( benefit( remained( after(
adjusting( for( tumour(staging,( therefore(making(this( reason( less( likely.(However,( it(
may(be(plausible(that(the(gender(difference(in(expression(of(PEDF(may(be(responsible(
for( the( survival( difference( seen.( In( our( cohort,( we( found( no( difference( in( PEDF(
expression(comparing(both(genders(in(age(groups(64(years(or(less(and(65(years(and(





Rectal( tumour( tissue( appeared( to( express( higher( mRNA( levels( of( PEDF( when(
compared( to( colonic( tumour( tissue,( however( this( was( not( confirmed( on(





our( results( showed( little( difference( in( the( expression( of( these( two( cell( lines( and(
therefore( there( may( be( other( cellular( factors( in( these( cell( lines( that( may( be(
responsible(for(the(expression(levels(shown.((
Mucinous(adenocarcinoma( tissue( showed(more(positive( tumour(expression(when(
compared( to( adenocarcinoma( tissue( on( immunohistochemical( staining.( This( is(




mucinous( adenocarcinoma( (Numata( ( et( al.( 2012)( and(hence( there(must(be(other(
influences,(yet(to(be(identified,(that(are(specific(to(mucin(producing(tumours(that(are(
responsible(for(the(higher(expression(levels(of(PEDF.(






activities( such( as( cellular( differentiation,( cell( growth( and( cell( cycle( control,(which(
typically(take(place(in(the(cytoplasm(in(eukaryotic(organisms.((































imaging.( Through( large( scale( clinical( trials( there( has( been( advancement( in( both(
chemotherapy( and( radiotherapy( regimes( that( can( be( offered( to( patients( with(
colorectal( cancer,( including( the( wide( spread( adoption( of( neo*adjuvant( chemo*
radiotherapy( for( locally( advanced( rectal( cancers( to( down( stage( tumours( prior( to(





colorectal( cancer( per( annum( (Cancer( Research( UK.( 2016;(










PEDF( has( been( demonstrated( to( inhibit( cellular( growth,( adhesion,(migration( and(







RKO,( HT115( and( HRT*18( cell( lines( were( chosen( for( this( part( of( the( study( as(
















with( 0.5%( crystal( violet( (v/v).( Analysis( was( performed( at( 540nm( using( a(
spectrophotometer.(Prior(to(reading(the(dye(was(solubilised(using(10%(acetic(acid.(
Data( from( at( least( 3( repeated( experimental( procedures( were( combined( and(
presented(in(this(chapter.((
4.2.4'In#vitro'tumour'cell'Matrigel'adhesion'assay'




formaldehyde( (v/v)( then( stained( with( 0.5%( crystal( violet( (v/v).( The( dye( was(
solubilised(using(10%(acetic(acid(and(analysed(using(a(spectrophotometer(at(540nm.(




were( incubated( for( 24( hours,( as( described( in( full( detail( in( section( 2.12.3.2.( After(
incubation,( a( straight*line( scratch(was(made( to( the( cellular(monolayer( down( the(
midpoint(of(each(well.(The(medium(was(then(removed(from(the(plates(carefully(and(
replaced(with(500µl(of(either(treatment(or(control(medium.(Analysis(was(performed(
using( EVOS( cell( imaging( system( (Life( Technologies,( Paisley,( UK)( and( images(were(












a( spectrophotometer( at( 540nm.( Data( from( at( least( 3( repeated( experimental(





significant( decrease( in( cellular( proliferation( with( varying( doses( of( rhPEDF( when(
compared(to(control(group((p=0.259(and(p=0.283(respectively(for(day(3(and(day(5)(
(Figure(4.1).((
There( was( no( statistically( significant( difference( seen( after( both( 3( and( 5( days( of(

























































Figure' 4.3.' ( Impact( of( rhPEDF(on( cellular( growth( after( 3( days( (A)( and(5(days( (B)( of( incubation,( in(











There(was(no(difference(observed( in( the(attachment(of(RKO(cells(with(any(of( the(
treatment(doses(of(rhPEDF(compared(to(the(control((p=0.603)((Figure(4.4).((






















































































This( significant( decrease( in( migration( rate( was( evident( for( all( doses( of( rhPEDF(
compared(to(untreated(HRT*18(cells.((rhPEDF(10ng/ml(vs(control(p=(0.002,(rhPEDF(
50ng/ml(p<0.001,(rhPEDF(100ng/ml(p<0.001)((Figure(4.8).(



































































































































Under( the( influence(of( treatment(with( rhPEDF(100ng/ml,( there(was(a( statistically(
significant( decrease( in( RKO( cellular( invasion( when( compared( to( control( medium(
(p=0.025);(however,( this(difference(was(not(witnessed(under( the( influence(of( the(
lower(doses(of(rhPEDF(treatments((10ng/ml(and(50ng/ml)((Figure(4.9).((

































































































Mortality( from( colorectal( cancer( is( frequently( related( to(metastatic( spread,(most(
commonly( affecting( the( liver( or( lungs.( Treatments( aimed( at( preventing( the(
metastatic(spread(of(colorectal(cancer(cells(could(therefore(prove(highly(beneficial(
for(the(survival(of(such(patients.(A(number(of(studies(have(demonstrated(that(the(
decreased( expression( of( PEDF( is( associated( with( the( increased( incidence( of(
metastases(in(a(range(of(solid(tumours((Uehara(et(al.(2004;(Halin(et(al.(2004;(Cai(et(
al.(2006b;(Dass(et(al.(2008;(Zhou(et(al.(2010;(Fitzgerald(et(al.(2012;(Ji(et(al.(2013).(It(is(
therefore( logical( to( hypothesise( that( administration( of( PEDF( may( suppress(






colorectal( cancer( cell( lines( appeared( to( significantly( decrease( the( rate( of( cellular(
migration.(This(effect(was(visible(in(HT115(cells(with(the(higher(doses(used(of(rhPEDF,(
50ng/ml(and(100ng/ml(vs(control((p=0.007(and(p<0.001,(respectively),(and(in(HRT*















and( invasion( by( down*regulating( fibronectin( and( subsequent( MMP2/MMP9(
reduction(via(p*ERK(and(p*AKT(signalling(pathways.(Correspondingly,(Tan(et#al((2010)(
found(a(20%(decrease(in(cellular(invasion(in(PEDF(treated(chondrosarcoma(cell(when(
compared( to( control( cells.( These( findings( support( our( results( presented( in( this(
chapter.((
In(the(adhesion(studies(presented(in(this(chapter,(treatment(with(100ng/ml(rhPEDF(
resulted( in(an( increase( in(cellular(attachment( in(HT115(colorectal(cancer(cell( lines(
(p=0.003).(Tan(et#al((2010)(found(a(similar(finding(when(examining(chondrosarcoma(
cells,(with( PEDF( treatment( significantly( enhancing( cellular( adhesion( to( collagen*1(
coated( surfaces( by( 204%(when( compared( to( untreated( cells.( Increased( adhesion(
certainly(presents(a(beneficial(effect(in(the(prevention(of(metastatic(progression,(by(
contributing(to(a(decreased(ability(for(the(cancer(cells(to(invade(and(migrate.((






2014),( we( found( no( significant( different( in( cellular( growth( rates( for( any( of( the(
colorectal( cancer( cell( lines( examined.( However( many( of( these( studies( that(
demonstrated( decreased( cellular( proliferation( with( PEDF( used( differing( methods(
from(the(ones(used(in(this(study;(in(particular(Hong(et#al((2014)(used(animal(models(
and(Matsumoto(et#al((2004)(studied(human(umbilical(vein(endothelial(cells(treated(
with( cultured( media( from( PEDF( transfected( hepatocellular( cancer( cells( and(







































In( order( for( optimal( wound( healing( to( take( place,( it( is( crucial( that( normal(
neovascularisation(occurs(during(the(proliferation(stage(of(wound(healing((Harding(
et(al.(2002).(During(a(normal(wound(healing(process,( the(many(soluble(mediators(
released( by(macrophages( initiate( this( stage.( The( process( of( neovascularisation( is(




VEGF*( or( FGFb*mediated( endothelial( cell( proliferation,( migration( and( inducing(


























up( were( classed( as( ‘healing’( and( those( that( had( either( not( decreased( in( size( or(
remained(static(in(size(or(increased(were(classed(as(‘non*healing’.((
5.2.3'RNA'isolation,'cDNA'synthesis,'RTQPCR'and'qPCR'
RNA( isolation(was( performed( using( TRI( reagent( kit( as( described( in( section( 2.8.1.(
Following(this(reverse(transcription(was(carried(out(using(a(high(capacity(RT(kit.(RT*




qPCR( was( performed( as( described( in( section( 2.8.8.( All( results( presented( were(
normalised( against( GAPDH( and( represent( combined( results( from( at( least( 3(
independent(repeats.((
5.2.4'Protein'isolation,'SDSQPAGE'and'Western'blotting''
The( method( for( isolating( protein( lysates( has( been( described( in( section( 2.9.1.(
Following(SDS*PAGE,(the(protein(was(transferred(onto(PVDF(membranes(and(probed(








a( 1:50( concentration( as( described( in( section( 2.5.( All( specimens( were( analysed(














as( representative( cell( lines( for( wound( healing.( Immunofluorescence( staining(was(
performed( as( described( in( section( 2.11.( The( primary( antibody( used( was( rabbit(































































































































































Figure' 5.12.( Representative( immunohistochemistry( images( for( non*healing( chronic( wound( tissue(
samples.( X100( magnification( used.( Scale( bar( represents( 50µm.( Red( arrows( show( the(
dermal/epidermal( junction,( with( no( difference( in( staining( seen.( Yellow( arrows( show( the( leading(








human( adipose( stem( cells( (HASC)( and( primary( dermal( fibroblasts( (DF)( when(
compared( to( HaCaT( keratinocyte( and( HECV( endothelial( cell( line.( This( was( also(
confirmed(by(protein(expression(with(western(blotting.(These(findings(support(those(
of( Francis( et# al# (2004)( and( Cai( et# al( (2006b),( who( demonstrated( high( mRNA(
expression(of(PEDF(in(fibroblasts.(It(has(also(been(shown(that(there(was(no(mRNA(




Immunofluorescence(and( immunocytochemical( staining(of( cells( found(a( tendency(
towards( cytoplasmic( staining( in( a( HaCaT( cell( line.( This( correlates( with( previous(
studies(that(demonstrated(that(expression(of(PEDF(protein(was(found(to(be(localised(
to( the( cytoplasm( of( keratinocytes( on( immunocytochemistry( and(
immunofluorescence(studies((Abe(et(al.(2010;(Li(et(al.(2011).(As(described(previously(
in( section( 3.4,( cytoplasmic( staining( supports( the( association( between( PEDF( and(
critical(cell(activities(such(as(cellular(differentiation,(cell(growth(and(cell(cycle(control.((











On( immunohistochemical( staining( studies,( PEDF( expression( was( observed( in( the(
dermis( layer,( blood( vessels( and( fibroblasts( on( both( ‘healing’( and( ‘non*healing’(
chronic(wound( samples.( There(was( a( tendency( for( higher( expression( at( both( the(
epidermal/dermal(junction(and(the(leading(wound(edge(in(the(‘healing’(wounds.((The(
observation(of( higher( PEDF(expression( in( the( epidermis( compared( to(dermis(was(
found(by(Abe(et#al#(2010),(which(contrasts(to(the(results(presented(here.(The(results(
somewhat(conflict(with(the(cellular(findings(of(mRNA(and(protein(expression(in(this(




previously(observed( in( immunohistochemical( staining( studies(of( colorectal( cancer(
tissue(as(described(in(section(3.3.2.((
In(conclusion,(PEDF(expression(was(highest(within(the(stem(cell(and(fibroblast(cell(







































The( results(presented( in(Chapter(5(confirmed( that(PEDF(expression(was(higher( in(
fibroblasts( compared( with( keratinocytes.( Abe( et# al( (2010)( demonstrated( that(












recombinant( PEDF( on( cellular( function( of( keratinocytes.( A( secondary( aim(was( to(












Additional( treatments(with(both(Focal(Adhesion(Kinase( inhibitor( (FAKi)(and(c*Met(
tyrosine(kinase(inhibitor((c*Mi)(were(also(used(further(in(this(chapter((as(described(in(











with( 0.5%( crystal( violet( (v/v).( Analysis( was( performed( at( 540nm( using( a(
spectrophotometer.(Prior( to(reading(the(dye(was(extracted(using(10%(acetic(acid.(
Data( from( at( least( 3( repeated( experimental( procedures( were( combined( and( are(
presented(in(this(chapter.((
6.2.4'Electric'CellQSubstrate'Impedance'Sensing'(ECIS)'assay'
ECIS(measures( the( rate( of( cells( initial( attachment( and( then( repopulating( an( area(
following(electrical(wounding,(by(using(gold(electrodes(within(a(well(plate(to(measure(
changes( in( resistance( and( impedance( over( time( and( is( described( in( full( detail( on(
section(2.12.2.1.(HaCaT(cells(were(seeded(at(a(seeding(density(of(10x104/150µl(with(

















After(3(days(of( incubation(with( rhPEDF,( the(dose(at(10ng/ml( resulted( in(an( initial(
statistically( significant( increase( in( HaCaT( cell( proliferation( compared( to( all( other(
tested( concentrations( of( rhPEDF( and( the( untreated( HaCaT( cells( (control( group)(
(p=0.002).( However,( after( 5( days( of( incubation,( there(were( no( significant( effects(
evident( on( HaCaT( cells( following( treatment( with( all( concentrations( of(





























































































































































































this( part( of( the( study,( 10nM( alone( and( 10nM( used( in( combination( with( rhPEDF(
































Figure' 6.6' ( Impact( of( FAKi( and( FAKi/rhPEDF( on( cellular( attachment( assessed( through( ECIS( assay.((
Change(in(electrode(resistance(from(baseline(is(shown(and(taken(as(representative(of(attachment(in(





in( electrode( resistance( from( post*wounding( baseline( is( shown( and( taken( as( representative( of(











































































































Figure' 6.9.' ( Impact( of( c*Mi( and( c*Mi/rhPEDF(on( cellular( attachment( assessed( through( ECIS( assay.((
Change(in(electrode(resistance(from(baseline(is(shown(and(taken(as(representative(of(attachment(in(




Figure' 6.10.' ( Impact( of( c*Mi( and( c*Mi/rhPEDF( on( cellular(migration( assessed( through( ECIS( assay.((
Change(in(electrode(resistance(from(post*wounding(baseline(is(shown(and(taken(as(representative(of(































































The( results( presented( in( this( chapter( showed( that( the( treatment( of( recombinant(
PEDF( significantly( increased( the( migration( of( the( HaCaT( (immortalised( human(
keratinocyte)(cell(line(as(assessed(by(ECIS(assay.(Whilst(there(was(an(initial(significant(
increase(in(cellular(growth(comparing(the(lower(treatment(dose(of(rhPEDF((10ng/ml)(












increased( that( it( would( result( in( decreased( migration( due( to( the( ‘sticky’( cells(
becoming(less(mobile.((
There( is( certainly( evidence( to( suggest( that( different( fragments( of( PEDF( are(
responsible( for( different(mechanisms(of( action( such( as( 34*mer( fragment( of( PEDF(
exhibiting( anti*angiogenic( effects( and( 44*mer( fragment( exhibiting( neurotrophic(
Chapter(6*(Role(of(PEDF(on(cellular(function(in(keratinocytes(
( 201( (
effects( (Filleur(et(al.(2005).(Whilst(human(recombinant(PEDF( is( full( length,( folding(
may(play(a(role(in(the(proper(function.((
Antibody(micro(array(showed(multiple(up*regulating(and(down*regulating(phosphor*






in( chronic(wound( edges,( in( contrast( to( acute(wounds( (Conway( et( al.( 2007).( PHA*
66572(is(a(second*generation(C*met(inhibitor(that(inhibits(enzymatic(activity(of(c*Met(
tyrosine( kinase.( (Our( results(demonstrated( that(HaCaT(migration(was( significantly(
increased(when( recombinant( PEDF( (50ng/ml)(was( combined(with( c*Met( inhibitor(
(10nM).(This(effect(can(be(somewhat(explained(by(the(fact(that(inhibiting(c*Met(may(
result(in(a(higher(concentration(of(HGF(which(is(known(to(increase(the(migration(of(
keratinocytes,( however( this( effect(was( only( visible(when( cMi(was( combined(with(
rhPEDF(and(not(when(used(alone.( It( is( likely( that(PEDF(treatment(results( in(c*Met(
expression,(with( cMi( blocking( c*Met,( therefore( these( two(opposite( actions( in( the(
system(results(in(the(net(outcome(described(above.(It(also(highlights(that(PEDF(may(
have(a(stronger(direct(action(on(keratinocyte(migration(by(some(other(means.((
FAK( protein( is( encoded( by( PTK2( gene( with( evidence( that( it( is( required( for(
keratinocyte( migration( (Gates( et( al.( 1994).( PF573228( is( a( potent( and( selective(








In( summary,( treatment( with( recombinant( PEDF( increases( the( migration( of(
keratinocytes( in( this( study,( in( contrary( to( earlier( published( work.( This( may( be(




































The( main( aims( of( this( thesis( were( to( elucidate,( in( more( detail( the( regulatory(
mechanisms( of( PEDF( in( wound( healing,( and( in( tumour( angiogenesis( related( to(
different(subtypes(of(colorectal(cancer,(by(examining(the(expression(profiles(of(PEDF(
in( colorectal( cancer( and( wounds( and( investigating( its( role( of( cellular( function( in(
colorectal(cancer(and(wounds(with(the(treatment(of(recombinant(PEDF.(This(was(in(










balance( between( pro*angiogenic( and( anti*angiogenic( mediators.( ( Physiological(
angiogenesis(occurs(when(this(balance( is(tightly(controlled,(such(as(during(normal(
wound( healing( processes,( however( pathological( angiogenesis( occurs( when( this(
complex(balance(goes(awry,(such(as(in(colorectal(cancer(or(chronic(wounds.(PEDF(is(
known(to(be(one(of(the(most(potent(natural(inhibitors(of(angiogenesis((Dawson(et(al.(
1999)( and( its( mechanism( of( action( is( to( arrest( endothelial( cell( proliferation( and(
Chapter(7*(General(Discussion(
( 205( (
migration.( However,( PEDF( is( selective( in( its( action,( discriminating( between(
endothelial( cells( forming( new( vessels( and( those( from( pre*existing( vessels( and(
therefore(targeting(mainly(abnormal(angiogenesis(with(newly(forming(vessels(only(
(Bouck( 2002).( It( is( therefore( logical( that( administration( of( endogenous( PEDF( can(
inhibit(aberrant(angiogenesis(leading(to(restoration(of(healthy(vasculature.(PEDF(is(
known( to( also( exhibit( neurotrophic,( neuroprotective,( anti*tumorigenic( and( anti*






PEDF( found( to( be( lower( in( colorectal( tumour( tissue(when( compared( to(matched(
normal(colorectal(tissue(from(colorectal(cancer(patients.(These(findings(are(similar(
to(those(of(Wågsäter(et#al((2010)(and(Ji(et#al((2013)(confirm(the(inverse(correlation(
between( PEDF( levels( and( pathological( angiogenesis.( There( was( also( a( significant(
decrease( in( the( expression( of( PEDF( with( worsening( tumour( grade,( suggesting( a(
possible( tumour( suppressor( role( and( may( indicate( a( potential( inhibitory( role( in(
primary(tumour(growth.(It(is(therefore(logical(to(suggest(that(elevation(of(PEDF(levels(







compared( to( colonic( tumours( and( higher( PEDF( expression( in( tumour( tissue( from(
female(colorectal(cancer(patients(when(compared(to(male(colorectal(cancer(patients.(





likely( that( PEDF( expression( should( be( less.(Díaz(et# al( (2008)( also( detected(higher(
mRNA(expression(of(PEDF(in(tissue(from(rectal(tumours(when(compared(to(colonic(
tumours,( however( aside( from( an( anatomical( difference( it( is( unclear(whether( the(
cellular(differences(are(responsible(for(the(difference(of(PEDF(expression(between(
cells(from(rectum(and(colon.(There(are(previous(studies(that(have(demonstrated(the(
opposite( gender( difference( in( expression( to( our( study( in( normal( subjects;( with(
healthy(males(having(higher(levels(of(PEDF(in(plasma(compared(to(healthy(females(
(Yamagishi(et(al.(2006;(Wågsäter(et(al.(2010);(however,(the(effect(in(colorectal(cancer(










18( cell( lines.( Similarly,( invasion( studies( showed( a( decrease( in( the( rate( of( RKO(
colorectal( cancer( cellular( invasion( with( the( treatment( of( recombinant( PEDF,( and(
whilst(not( significant( there(was(a( similar( trend(observed( in( the(HRT*18(colorectal(
cancer(cell(line.(We(also(observed(an(increase(in(cellular(adhesion(with(treatment(of(
recombinant(PEDF(in(the(HT115(colorectal(cancer(cell(line.(To(date(the(role(of(PEDF(
treatment( on( colorectal( cancer( cellular( function( has( not( been( studied,( however(
published( studies( relating( to( breast( cancer( and( chondrosarcoma( confirmed(
















have(been( suggested(as(a(method(of( testing(PEDF(as(a( therapeutic( cancer(agent;(
either(as(a(viral(vector((Wu(et(al.(2012)((or(direct(administration(of(unmodified(PEDF(
into( tumours( (Abramson( et( al.( 2003).( However,( to( date( there( has( been( limited(











fibroblasts( and( positive( staining( of( dermis( and( dermal*epidermal( junction,( which(




the( treatment( of( recombinant( PEDF( significantly( increased( the( migration( of(




perhaps( due( to( folding( of( the( human( recombinant( PEDF( that( various( fragments(
available(were(responsible(for(the(differing(results.((
The( addition( of( either( focal( adhesion( kinase( inhibitor( or( c*Met( tyrosine( kinase(























both( colorectal( cancer( and( wound( healing.( Whilst( a( number( of( important(
observations( have( been( identified,( an( additional( number( of( questions( requiring(
further(assessment(have(been(highlighted.(These(are(summarised(below:(
1.(The(expression(profile(of(PEDF(should(be(performed(comparing(normal(subjects(
and( those( patients( with( colorectal( cancer( (with( a( range( of( clinicopathological(




survival(differences(seen(between( the(genders.( It( is(also(worth(exploring(why( the(
gender(differences(may(exist*(are( there(other( factors( influencing(PEDF(expression(
perhaps(related(to(hormonal(differences(between(genders?(
2.( (The( further(assessment( into( the(differing(expression( levels(of(PEDF(comparing(




























the( improved( knowledge( of( the( interactions( between( PEDF( and( pathological(
processes(seen(in(colorectal(cancer(and(chronic(wound(healing,(it(may(result(in(the(
improvement(of(outcomes(for(patient(who(suffer(with(these(diseases.('
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